{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2021.11.10.21266063v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2021.11.10.21266063v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2021.11.10.21266063v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. TTS presents similarly to autoimmune heparin-induced thrombocytopenia. Twelve cases of cerebral venous sinus thrombosis following Janssen\/Johnson \u0026amp; Johnson (Ad26.COV2.S) COVID-19 vaccination have been described.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EObjective\u003C\/strong\u003E Describe surveillance data and reporting rates of TTS cases following COVID-19 vaccination.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EDesign\u003C\/strong\u003E Case series.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003ESetting\u003C\/strong\u003E United States\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EPatients\u003C\/strong\u003E Case-patients reported to the Vaccine Adverse Event Reporting System (VAERS) receiving COVID-19 vaccine from December 14, 2020 through August 31, 2021, with thrombocytopenia and thrombosis (excluding isolated ischemic stroke or myocardial infarction). If thrombosis was only in an extremity vein or pulmonary embolism, a positive enzyme-linked immunosorbent assay for anti-platelet factor 4 antibody was required.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EMeasurements\u003C\/strong\u003E Reporting rates (cases\/million vaccine doses) and descriptive epidemiology.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-8\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E 52 TTS cases were confirmed following Ad26.COV2.S (n=50) or mRNA-based COVID-19 (n=2) vaccination. TTS reporting rates were 3.55 per million (Ad26.COV2.S) and 0.0057 per million (mRNA-based COVID-19 vaccines). Median age of patients with TTS following Ad26.COV2.S vaccination was 43.5 years (range: 18\u201370); 70% were female. Both TTS cases following mRNA-based COVID-19 vaccination occurred in males aged \u0026gt;50 years. All cases following Ad26.COV2.S vaccination involved hospitalization including 32 (64%) with intensive care unit admission. Outcomes of hospitalizations following Ad26.COV2.S vaccination included death (12%), discharge to post-acute care (16%), and discharge home (72%).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-9\u0022\u003E\u003Cstrong\u003ELimitations\u003C\/strong\u003E Under-reporting and incomplete case follow-up.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-10\u0022\u003E\u003Cstrong\u003EConclusion\u003C\/strong\u003E TTS is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the two cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-11\u0022\u003E\u003Cstrong\u003EFunding Source\u003C\/strong\u003E CDC\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-11\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EIntroduction\u003C\/h2\u003E\u003Cp id=\u0022p-24\u0022\u003EThrombosis with thrombocytopenia syndrome (TTS), also referred to as vaccine-induced thrombotic thrombocytopenia (VITT), is a rare condition recently described among persons who received the adenoviral-vectored COVID-19 vaccines made by Janssen\/Johnson \u0026amp; Johnson (Ad26.COV2.S) and Oxford\/AstraZeneca (ChAdOx1 nCoV-19) [\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E]. Initial recognition of the condition precipitated a pause in the administration of Ad26.COV2.S in the United States and modifications of ChAdOx1 nCoV-19 vaccine policy in other countries [\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E]. Based on the distinctive clinical and laboratory features of the syndrome, epidemiologic clustering of timing after receipt of adenoviral-vectored COVID-19 vaccines, and plausible pathogenic mechanisms, causal associations between receipt of adenoviral vectored vaccines and TTS are likely [\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EReported rates of TTS after ChAdOx1 nCoV-19, which is not approved or authorized for use in the United States, range from 13\u201339 cases per million vaccine doses administered, depending on the publication [\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]. The first reports of TTS following ChAdOx1 nCoV-19 described a high case-fatality rate and features shared with autoimmune or spontaneous heparin-induced thrombocytopenia (HIT) [\u003Ca id=\u0022xref-ref-1-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E], including thrombocytopenia, thrombosis, and the presence of antibodies to platelet factor 4 (PF4) [\u003Ca id=\u0022xref-ref-1-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-3-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E] in the absence of prior exposure to heparin. These reports described positive results for antibody to PF4 measured by enzyme-linked immunosorbent assay (ELISA) and in many cases, positive results for various functional HIT platelet assays, which evaluate the ability of anti-PF4 antibodies to activate platelets and cause thrombosis [\u003Ca id=\u0022xref-ref-1-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-3-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E]. Preliminary hypotheses on the pathogenesis of TTS generally posit mechanisms related to the adenovirus vector platform, including triggering of HIT-like antibodies from adenoviral DNA, from cell-line-derived factors, or from splice variants of the SARS-CoV-2 spike protein caused by the adenoviral vector platform [\u003Ca id=\u0022xref-ref-1-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003ETTS after ChAdOx1 nCoV-19 vaccine receipt has been described in detail [\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E]. In the United States, the first 12 cases of TTS following Ad26.COV2.S involving cerebral venous sinus thrombosis were described in a preliminary report [\u003Ca id=\u0022xref-ref-5-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E]; and additional case reports have been published including one case of TTS following mRNA COVID-19 vaccination [\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003EThis report is the first comprehensive review of TTS following COVID-19 vaccination in the United States. We describe epidemiology and clinical characteristics of the case reports to inform clinicians and public health officials.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-12\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMethods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EData Sources\u003C\/h3\u003E\u003Cp id=\u0022p-28\u0022\u003EThe Vaccine Adverse Events Reporting System (VAERS) is a passive surveillance (spontaneous reporting) system for adverse events following immunization jointly administered by the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) [\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E]. VAERS accepts all reports of possible adverse events following vaccination from patients, clinicians, vaccine manufacturers, and the public, regardless of clinical severity of the event or its causal association with vaccination. The VAERS database was searched for potential reports of TTS received during December 14, 2020 through August 31, 2021, in the following manner: 1) on April 9, 2021, a retrospective search was conducted for reports received during December 14, 2020 through April 8, 2021; 2) prospective searches were conducted beginning on April 9, 2021. All data for this report were retrieved by August 31, 2021. Reports were screened for Medical Dictionary for Regulatory Activities (MedDRA) standardized codes (Preferred Terms [PTs]) [\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E] assigned to reports by professional medical coders, as well as language in the symptom or laboratory text fields of the report, that described symptoms, laboratory values, and medical conditions that could indicate TTS (see Supplemental Methods).\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EVaccine administration data were reported by public health jurisdictions to CDC (Supplemental Methods) [\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E].\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ECase definitions\u003C\/h3\u003E\u003Cp id=\u0022p-30\u0022\u003EWe used the following case definitions for TTS. A Tier 1 case had thrombosis in an unusual location for a thrombus (i.e., cerebral vein, visceral artery or vein, extremity artery, central artery or vein) and new-onset thrombocytopenia (i.e., platelet count \u0026lt;150,000\/\u00b5L) occurring any time after receipt of a COVID-19 vaccine. Tier 2 cases had new-onset thrombocytopenia, thrombosis in an extremity vein or pulmonary artery in the absence of thrombosis at a Tier 1 location, and a positive anti-PF4 antibody ELISA test or functional HIT platelet test occurring any time after receipt of COVID-19 vaccine. Given the very unusual clinical presentation of the Tier 1 cases, additional laboratory abnormalities were not required, whereas the inclusion of positive HIT testing results for cases with only common thromboses (Tier 2) was intended to limit the number of potential false positive cases.\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EConfirmation of case status required review of patient data from medical records and in some cases also discussion with providers. All cases were also reviewed with clinicians from CDC\u2019s Clinical Immunization Safety Assessment (CISA) Project (Supplemental Methods) [\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E].\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EData analysis\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003ETTS reporting rates were calculated per million doses of Ad26.COV2.S vaccine administered and stratified by sex and age group. Overall reporting rates were calculated per million mRNA COVID-19 vaccine (i.e., Moderna and Pfizer-BioNTech) doses administered. Booster dose administration was excluded from reporting rate calculations.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EData were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at CDC. REDCap is a secure, web-based software platform designed to support data entry and management [\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E]. Descriptive analysis of demographic and clinical data associated with TTS cases was conducted. Demographics, risk factors for thrombosis, platelet nadir, and timing of clinical presentation were compared between Tier 1 and Tier 2 cases using chi-square or Fisher\u2019s exact test, as appropriate, for categorical variables and using Wilcoxon rank-sum test for continuous variables. To permit comparisons with other reports concerning TTS, supplemental results describe whether cases met definite or probable VITT criteria established by the United Kingdom (UK) Expert Hematology Panel [\u003Ca id=\u0022xref-ref-17-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E]. Venous thromboembolism risk factors were assessed according to published literature [\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-25-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-25\u0022\u003E25\u003C\/a\u003E]. Data analyses were conducted with SAS 9.4 (SAS Institute, Cary, NC).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EHuman subjects\u003C\/h3\u003E\u003Cp id=\u0022p-34\u0022\u003EThis activity was reviewed by the CDC Human Subjects Office, determined to be a non-research public health surveillance project, and was conducted consistent with applicable federal law and policy (see e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. \u00a7241(d); 5 U.S.C. \u00a7552a; 44 U.S.C. \u00a73501 et seq).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ERole of the Funding source\u003C\/h3\u003E\u003Cp id=\u0022p-35\u0022\u003EThis activity was funded by CDC. CDC and non-CDC co-authors conducted the investigations; performed collection, management, analysis, and interpretation of the data; were involved in preparation, review, and approval of the manuscript; and made the decision to submit the manuscript for publication.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-18\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EResults\u003C\/h2\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ETTS reporting rates\u003C\/h3\u003E\u003Cp id=\u0022p-36\u0022\u003EOf 579,301 total reports to VAERS after COVID-19 vaccination during the analytic period, 1,122 were identified as potential cases based on initial screening of VAERS reports. Of these, 51 are pending adjudication, 6 had insufficient information was contained in the report to determine (e.g., the report included information about thrombosis only and no provider listed to obtain further information) and 953 did not meet case definition criteria. Of the 112 remaining reports, confirmed to have thrombosis and thrombocytopenia after COVID-19 (i.e., potentially meeting criteria for the TTS case definition), 66 reports were excluded because they were duplicate reports (n=30); active COVID-19 infection was documented at the time of TTS diagnosis (n=5); thrombocytopenia was not new-onset (n=2); TTS symptoms preceded COVID-19 vaccination (n=3); thrombocytopenia was most likely artifactual (n=1); or thrombosis was more likely due to another cause (n=19). After these exclusions, 52 reports were determined to meet the CDC case definition for TTS: 50 cases after Ad26.COV2.S and 2 after mRNA COVID-19 vaccination (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/11\/14\/2021.11.10.21266063\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Reports to the Vaccine Adverse Event Reporting System (VAERS) confirmed to be thrombosis with thrombocytopenia syndrome (TTS), United States, December 2020\u0026#x2013;August 2021\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1807536204\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Reports to the Vaccine Adverse Event Reporting System (VAERS) confirmed to be thrombosis with thrombocytopenia syndrome (TTS), United States, December 2020\u0026#x2013;August 2021\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/11\/14\/2021.11.10.21266063\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022290\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/11\/14\/2021.11.10.21266063\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022290\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/11\/14\/2021.11.10.21266063\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2021\/11\/14\/2021.11.10.21266063\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1:\u003C\/span\u003E \u003Cp id=\u0022p-37\u0022 class=\u0022first-child\u0022\u003EReports to the Vaccine Adverse Event Reporting System (VAERS) confirmed to be thrombosis with thrombocytopenia syndrome (TTS), United States, December 2020\u2013August 2021\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-38\u0022\u003EGiven administration of 14.1 million doses of Ad26.COV2.S and 351 million doses of mRNA COVID-19 vaccines, the overall TTS reporting rate (per million vaccine doses administered) was 3.55 after Ad26.COV2.S and 0.0057 after mRNA COVID-19 vaccination. Reporting rates were highest following receipt of Ad26.COV2.S vaccine among females aged 30-39 years (10.6 per million doses) and 40-49 years (8.12 per million doses) (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/436351\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/436351\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/436351\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1:\u003C\/span\u003E \u003Cp id=\u0022p-39\u0022 class=\u0022first-child\u0022\u003EReporting rates for thrombosis with thrombocytopenia syndrome (TTS) following receipt of Ad26.COV2.S (Janssen\/Johnson \u0026amp; Johnson COVID-19) and mRNA COVID-19 vaccines (Pfizer-BioNTech BNR162b2 or Moderna mRNA-1263)\u2014United States, December 2020\u2013August 2021\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-20\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDemographics, location of thrombosis, treatment, and outcomes of TTS cases following Ad26.COV2.S vaccination\u003C\/h3\u003E\u003Cp id=\u0022p-40\u0022\u003EThe 50 TTS cases reported following Ad26.COV2.S vaccination occurred in patients with median age of 43.5 years (range: 18-70; interquartile range 36-52); 35 (70%) were female and 37 (74%) were white (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E). Forty-two cases were Tier 1 (84%) and 8 (16%) were Tier 2. Either a venous thrombosis or thromboembolism was found in 49\/50 cases (98%). The most common anatomic region for thrombosis was cerebral venous sinuses (n=27; 54%). Eight TTS cases (16%) had arterial thrombosis (including 7 also with a venous thrombosis or thromboembolism). Thrombosis was present in more than one anatomic region for 36 cases (52%). A recognized risk factor for venous thromboembolism [\u003Ca id=\u0022xref-ref-24-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-25-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-25\u0022\u003E25\u003C\/a\u003E] was present in 33 (66%) of cases, most commonly obesity (n=23; 46%). No TTS cases occurred in females who were pregnant or within 12 weeks postpartum, or in patients with known thrombophilia. Seven cases (14%) occurred in patients with prior SARS-CoV-2 infection; demographics, presence of risk factors for venous thrombosis, and timing of illness did not differ significantly between cases with cerebral venous sinus thrombosis and other cases (Supplemental Table 1).\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/436353\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/436353\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2:\u003C\/span\u003E \u003Cp id=\u0022p-41\u0022 class=\u0022first-child\u0022\u003ECharacteristics of persons with thrombosis with thrombocytopenia syndrome reported following receipt of Ad26.COV2.S (Janssen\/Johnson \u0026amp; Johnson COVID-19 Vaccine)\u2014United States, December 2020\u2013August 2021\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-42\u0022\u003EHeparin was administered to manage thrombosis in 11\/13 cases (85%) presenting before the pause in use of Ad26.COV2.S and 10\/37 (27%) of the cases presenting after. Other treatments used to manage TTS were non-heparin anticoagulants (n=46; 92%), intravenous immunoglobulin (n=33; 66%), corticosteroids (n=21; 42%), platelet transfusion (n=18; 36%), and plasmapheresis (n=3; 6%). A surgical or radiologic procedure was performed in 20 cases (40%) to manage thrombosis or suspected complication, of which the most common was thrombectomy or catheter-directed thrombolysis (n=15; 30%).\u003C\/p\u003E\u003Cp id=\u0022p-43\u0022\u003EAll patients were hospitalized; 32 (64%) were admitted to an intensive care unit (ICU). Outcomes of the initial hospitalization were discharge home (n=36; 72%), discharge to post-acute care facility (n=8; 16%), and death (n=6; 12%). For patients discharged from the hospital alive, median hospital length of stay was 6 days (range: 1-132 days) (Supplemental Figure 1).\u003C\/p\u003E\u003Cp id=\u0022p-44\u0022\u003EAll sixr deaths occurred in non-Hispanic white patients with cerebral venous sinus thrombosis; five had superior sagittal sinus thrombosis. Four decedents were female; ages ranged from 29-52 years (median: 41 years). Four of the decedents had underlying medical conditions (n=4 with a risk factor for venous thromboembolism [obesity]; n=1 with asthma; n=1 with hyperlipidemia; n=1 with seizure disorder). None had documentation of prior SARS-CoV-2 infection. None received heparin. All had cerebral hemorrhage and evidence of mass effect on initial neuroimaging and died within 2 days of presentation. Median platelet count nadir among decedents was 15,500\/\u00b5L (range: 9,000-44,000\/\u00b5L). Anti-PF4 antibody ELISA testing was performed for four decedents; all tests were positive with optical density values \u0026gt;2.0.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-21\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ELaboratory findings and clinical presentation of TTS cases following Ad26.COV2.S vaccination\u003C\/h3\u003E\u003Cp id=\u0022p-45\u0022\u003ESymptoms began a median of 10 days after vaccination (range: 0-18 days) (\u003Ca id=\u0022xref-table-wrap-2-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E; Supplemental Table 2). The most common initial symptom reported among cases was headache (n=35; 70%); headache was an initial symptom for 24\/27 (89%) of cases with cerebral venous sinus thrombosis and for 11\/23 (48%) of cases without cerebral venous sinus thrombosis (Supplemental table 2). Nineteen (38%) patients had at least one prior healthcare encounter for evaluation of symptoms with discharge home prior to a hospital admission and TTS diagnosis; of these, 9 were documented to have thrombocytopenia during the initial encounter (i.e., before hospital admission). In 7 cases, radiologic evaluation on initial presentation was negative for thrombosis, including 5 (of whom one later died) with initial radiologic examination negative at a site where thrombosis was later diagnosed (e.g., negative initial computed tomography venogram of the head in a patient later found to have cerebral venous sinus thrombosis on imaging).\u003C\/p\u003E\u003Cp id=\u0022p-46\u0022\u003EThrombocytopenia was present during TTS hospitalization with the exception of one case of pulmonary embolism in which thrombocytopenia was found only at the first emergency department visit following Ad26.COV2.S vaccination. The platelet count had returned to normal by the time the patient was hospitalized 6 days later with pulmonary embolism and a positive anti-PF4 antibody ELISA test.\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003EThe median platelet nadir was 32,500\/\u00b5L (range: 5,000-127,000) (\u003Ca id=\u0022xref-table-wrap-4-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E; Supplemental Figure 3). Platelet nadirs differed by clinical characteristics and course of disease. All patients with hospital length of stay \u0026gt;20 days (n=6) had platelet count nadirs \u0026lt;25,000\/\u00b5L (Supplemental figure 4). All patients who were admitted to the hospital \u0026gt;12 days after symptom onset (n=6) had platelet nadirs \u0026gt;75,000\/\u00b5L (Supplemental figure 5). Median platelet nadir for cases admitted to the ICU was 27,500\/\u00b5L (range: 5,000-127,000\/\u00b5L) vs 44,000\/\u00b5L for cases not admitted to the ICU (range: 8,000-112,000\/\u00b5L). For 39 patients discharged from the hospital alive with discharge platelet counts available, median platelet count at discharge was 167,000\/\u00b5L (range: 91,000-469,000\/\u00b5L) (\u003Ca id=\u0022xref-table-wrap-4-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E). Of these patients, 16 (41%) had platelet count \u0026lt;150,000\/\u00b5L at discharge.\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/436349\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/436349\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/436349\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3:\u003C\/span\u003E \u003Cp id=\u0022p-48\u0022 class=\u0022first-child\u0022\u003EIn-hospital treatment and outcomes following hospitalization for thrombosis with thrombocytopenia syndrome cases following receipt of Ad26.COV2.S (Janssen\/Johnson \u0026amp; Johnson COVID-19 Vaccine)\u2014United States, December 2020\u2013August 2021\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T4\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/436347\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup last\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/436347\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 4:\u003C\/span\u003E \u003Cp id=\u0022p-49\u0022 class=\u0022first-child\u0022\u003ELaboratory results obtained during initial hospitalizations among persons with thrombosis with thrombocytopenia syndrome following receipt of Ad26.COV2.S (Janssen\/Johnson \u0026amp; Johnson COVID-19 Vaccine)\u2014United States, December 2020\u2013August 2021\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-50\u0022\u003EAnti-PF4 antibody ELISA results were positive in 42 (84%), negative in 3 (6%), and not performed in 5 (10%) cases (\u003Ca id=\u0022xref-table-wrap-4-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E). Functional HIT platelet testing results were available for 34 and positive in 11. Of the three TTS cases following Ad26.COV2.S vaccination with negative anti-PF4 antibody ELISA results, two occurred in male patients; two were Hispanic or non-white race. All had underlying medical conditions, including hyperlipidemia (n=2) and prior vascular disease (n=2; history of myocardial infarction or ischemic stroke). All had platelet nadir \u0026gt;100,000\/\u00b5L. Two had cerebral venous sinus thrombosis and one had abdominal vein thrombosis.\u003C\/p\u003E\u003Cp id=\u0022p-51\u0022\u003EA thrombophilia evaluation (including testing for one or more of the following: lupus anticoagulant; cardiolipin, \u03b2\u003Csub\u003E2\u003C\/sub\u003E-glycoprotein I, phosphatidylserine antibodies; prothrombin G20210A mutation; Factor V Leiden mutation) was reported for 30 cases (60%); results for these 30 did not suggest an alternative cause for thrombosis (\u003Ca id=\u0022xref-table-wrap-4-4\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003ESupplemental Results describe evaluation of U.S. TTS cases following Ad26.COV2.S vaccination using the U.K. Expert Hematology Panel VITT case definition.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-22\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDescription of TTS cases following mRNA COVID-19 vaccination\u003C\/h3\u003E\u003Cp id=\u0022p-53\u0022\u003ETwo TTS cases were identified following mRNA COVID-19 vaccination, both after dose 2 of the Moderna COVID-19 Vaccine. Both occurred in males aged over 50 years who were either non-white or Hispanic and had cardiovascular risk factors (hyperlipidemia and hypertension in both; diabetes in one). Both had cerebral venous sinus thrombosis, and one also had deep vein thrombosis and pulmonary emboli. Symptom onset occurred 2 and 11 days after vaccination. Platelet nadirs were \u0026lt;25,000\/\u00b5L for one case and between 50,000-100,000\/\u00b5L for the other. Anti-PF4 antibody ELISA results were positive with optical density values \u0026gt;2.0. One patient received intensive care and died during hospitalization; the other was discharged home.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-23\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDiscussion\u003C\/h2\u003E\u003Cp id=\u0022p-54\u0022\u003EThis case series provides further evidence that TTS is a rare but serious condition causally associated with receipt of the Ad26.COV2.S vaccine. TTS is characterized predominantly by cerebral venous sinus thrombosis or venous thromboembolism with thrombocytopenia. Continued vigilance for TTS in patients with a history of Ad26.COV2.S vaccination, thrombocytopenia, and compatible symptoms is needed to ensure proper evaluation (e.g., anti-PF4 antibody ELISA testing) and treatment (e.g., use of non-heparin anticoagulation) of these patients [\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E]. Additionally, this case series provides information to contextualize two reported TTS cases following mRNA COVID-19 vaccination. Both cases were men with cardiovascular risk factors. The different demographic characteristics for the two cases and the much lower reporting rate for TTS following mRNA-based COVID-19 vaccines suggest that these 2 cases represent background cases or a different pathogenesis than the cases associated with AD26.COV2.S vaccine.\u003C\/p\u003E\u003Cp id=\u0022p-55\u0022\u003EThis case series highlights important clinical characteristics of TTS following Ad26.COV2.S vaccination. For example, although arterial thrombosis does occur and there are case reports of TTS involving only arterial thrombosis [\u003Ca id=\u0022xref-ref-27-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-28-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-28\u0022\u003E28\u003C\/a\u003E], TTS following Ad26.COV2.S vaccination is largely a syndrome of venous thrombosis or thromboembolism. The frequency of ICU admission, need for procedures to address thrombosis or complications, long length of stay, and fatalities confirm that TTS occurring after Ad26.COV2.S vaccination is a serious condition. The case-fatality presented in this U.S. series (12% for cases following Ad26.COV2.S vaccination) is lower than the 22% case-fatality for TTS following ChAdOx1 nCoV-19 vaccination described from the UK [\u003Ca id=\u0022xref-ref-16-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E]. We found higher rates of TTS among females after Ad26.COV2.S, whereas no male\/female predominance was seen in a large UK series of TTS following ChAdOx1 nCoV-19 vaccination [\u003Ca id=\u0022xref-ref-16-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E]. Consistent with UK data is our finding among TTS cases following Ad26.COV2.S vaccination, the platelet count nadir may be a marker of severity or how quickly symptoms progress.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003EThe diagnosis of TTS can be challenging. A negative initial radiologic examination in our cases did not preclude later development of thrombosis in the same location. Repeated imaging may be needed for patients who present more than once with persistent or progressive signs and symptoms of TTS. Headache was the most common initial symptom not only for patients with cerebral venous sinus thrombosis but also extracranial thrombosis, with onset usually beginning several days after vaccination. In patients with prolonged or persistent headache and thrombocytopenia following Ad26.COV2.S vaccination, search for extracranial sites of thrombosis should be considered. Some investigators recommend treatment for TTS in patients with severe headache, thrombocytopenia, elevated D-dimers, and positive anti-PF4 antibody ELISA tests after ChAdOx1 nCoV-19 vaccination, even in the absence of documented thrombosis [\u003Ca id=\u0022xref-ref-29-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-29\u0022\u003E29\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-57\u0022\u003EThe TTS reporting rate from U.S. VAERS data following Ad26.COV2.S vaccination (3.55 cases\/million doses) is lower than rates (13-39 cases\/million doses) reported for TTS following ChAdOx1 nCoV-19 vaccination in other countries [\u003Ca id=\u0022xref-ref-2-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-9-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E]. Although information about TTS was disseminated by the U.S. media [\u003Ca id=\u0022xref-ref-30-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-30\u0022\u003E30\u003C\/a\u003E], differences in reporting rates could be associated with relative under-reporting or under-ascertainment in the United States, true differences in TTS risk after Ad26.COV2.S vs. ChAdOx1 nCoV-19 vaccination, differences in the populations vaccinated, or other factors.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003EA recent report estimated that the background incidence of cerebral venous sinus thrombosis with thrombocytopenia during the pre-COVID-19 era (2018-2019) [Amanda Payne, personal communication] was 0.16-0.22 cases per 100,000 persons per year. Based on these data, the expected 2-week incidence per million persons is 0.0062, an estimate similar to the reporting rate for TTS following mRNA COVID-19 vaccination (0.0057) found here. The small number of TTS cases reported following mRNA COVID-19 vaccination were among patients with different demographic characteristics (older, non-white males) and medical histories (e.g., presence of cardiovascular risk factors) than most cases reported following Ad26.COV2.S vaccination. These findings suggest that the TTS cases following mRNA COVID-19 vaccination represent a background rate of autoimmune HIT or TTS associated with a different risk factor than cases associated with Ad6.COV2.S vaccination.\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EBased on positive results from functional HIT platelet assays among early case reports, the pathophysiology of TTS following ChAdOx1 nCoV-19 vaccine receipt is believed to be similar to autoimmune HIT in which anti-PF4 antibodies activate platelets and cause thrombosis [\u003Ca id=\u0022xref-ref-1-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-3-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E]. The binding site for anti-PF4 antibodies in patients with TTS reported after ChAdOx1 nCoV-19 vaccination is identical to the heparin binding site for HIT patients [\u003Ca id=\u0022xref-ref-31-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E]. However, as was described with the initial 12 cases of cerebral venous sinus thrombosis with thrombocytopenia following Ad26.COV2.S vaccination, most TTS cases reported following Ad26.COV2.S vaccination for whom a serotonin release assay (the most common functional HIT platelet assay performed) was performed had negative results. Other investigators have described assay modifications needed for the serotonin release assay to identify patients with TTS following ChAdOx1 nCoV-19 vaccination [\u003Ca id=\u0022xref-ref-32-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-32\u0022\u003E32\u003C\/a\u003E] and the same modifications in testing procedure may be needed for TTS following Ad26.COV2.S vaccination.\u003C\/p\u003E\u003Cp id=\u0022p-60\u0022\u003ECompared to the UK Expert Hematology Panel case definitions for \u201cDefinite VITT\u201d or \u201cProbable VITT\u201d [\u003Ca id=\u0022xref-ref-17-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E], the TTS case definition used here excludes cases without thrombocytopenia and can include cases with negative anti-PF4 antibody ELISA results, symptom onset less than 5 days after vaccination, and with normal D-dimer results. Our case definition appears to have greater sensitivity (Supplemental Results; \u003Cem\u003EComparison with UK Expert Hematology Panel case definition)\u003C\/em\u003E and may be more appropriate for a new condition in which the spectrum of disease is being actively investigated. However, consideration may be needed for inclusion of additional presentations such as positive anti-PF4 antibody ELISA lacking either thrombosis or thrombocytopenia or requiring cases following mRNA COVID-19 vaccination (or other non-adenoviral-vector COVID-19 vaccines in the future) to have positive anti-PF4 antibody ELISA results. Because evidence to date is insufficient to conclude that TTS is epidemiologically linked to receipt of mRNA COVID-19 vaccines, this requirement might limit false positives for the rare events that meet the TTS case definition following mRNA COVID-19 vaccination.\u003C\/p\u003E\u003Cp id=\u0022p-61\u0022\u003EThis report is subject to limitations. VAERS is a passive surveillance system, so the TTS reporting rates described likely underestimate true rates of occurrence. In addition, lack of anti-PF4 antibody ELISA testing could lead to both underreporting and underrepresentation of Tier 2 cases, compared to Tier 1 TTS cases. However, a strength of the current analysis is that because the COVID-19 immunization program was federally coordinated, all U.S. public health jurisdictions reported the number of COVID-19 vaccines that were administered, allowing a better estimate of reporting rates than usually possible when using VAERS data.\u003C\/p\u003E\u003Cp id=\u0022p-62\u0022\u003EWe estimate reporting rates of TTS following COVID-19 vaccination and describe the epidemiology of this emerging syndrome through a systematic surveillance effort. The epidemiology and hypothesized pathogenesis of TTS support a causal association with receipt of the Ad26.COV2.S COVID-19 vaccine. However, the much lower reported rates and difference in demographics for TTS cases following mRNA-based COVID-19 vaccines suggest that reports occurring after mRNA-based vaccine likely represents a background rate of cases of autoimmune HIT. Continued vigilance for TTS cases following Ad26.COV2.S vaccination is needed; the reporting rates and epidemiologic data about TTS following Ad26.COV2.S vaccination will be useful in formulating benefit-risk assessments for COVID-19 immunization programs in the United States and other countries [\u003Ca id=\u0022xref-ref-33-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E-\u003Ca id=\u0022xref-ref-34-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-34\u0022\u003E34\u003C\/a\u003E].\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-25\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-63\u0022\u003EDue to legal restrictions related to confidentiality, the original data are not available to the public.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-26\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFinancial support\u003C\/h2\u003E\u003Cp id=\u0022p-64\u0022\u003Ethe corresponding author conducted this work as part of his official duties as a U.S. government employee\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-27\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECDC disclaimer\u003C\/h2\u003E\u003Cp id=\u0022p-65\u0022\u003EThe findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC) or the Food and Drug Administration (FDA). Mention of a product or company name is for identification purposes only and does not constitute endorsement by the CDC and FDA.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-28\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\/Conflicts of interest\u003C\/h2\u003E\u003Cp id=\u0022p-67\u0022\u003EThis work was supported by the Centers for Disease Control and Prevention Clinical Immunization Safety Assessment (CISA] project contracts 200-2012-53664-0005 to Johns Hopkins University, 200-2012-50430-0005 to Vanderbilt University Medical Center, 200-2012-53663-0011 to Duke University, and 200-2012-53665-0005 to Columbia University.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgements\u003C\/h2\u003E\u003Cp id=\u0022p-66\u0022\u003EWe would like to thank the following CDC staff who contributed to this manuscript without compensation aside from their salaries. For data collection: Suzanne Beavers, MD (CDC COVID-19 Response), Rebecca Byram, MS, MPH (CDC COVID-19 Response), Kathy Byrd, MD, MPH (CDC COVID-19 Response), Margaret Cortese, MD (CDC COVID-19 Response), Alice Guh, MD, MPH (CDC COVID-19 Response), Theresa A. Harrington, MD, MPH\u0026amp;TM (CDC COVID-19 Response), Amelia Jazwa, MSPH (CDC COVID-19 Response), Anamika Khatri-Dua, MD (CDC COVID-19 Response), Susan Lukacs, DO, MSPH (CDC COVID-19 Response), Michael M. McNeil, MD, MPH (CDC COVID-19 Response), Duong Nguyen, DO (CDC COVID-19 Response), Monica Parise, MD (CDC COVID-19 Response), Agam Rao (CDC COVID-19 Response), Allan Taylor, MD, MPH (CDC COVID-19 Response). For leadership and support: Denise Cardo, MD (CDC COVID-19 Response), Frank DeStefano (CDC COVID-19 Response). We would also like to thank the following individuals who contributed to this manuscript with funding support through the CISA Project. For programmatic support: Paula Campbell, MS, MPH (Vanderbilt University) and Braxton Hern, BS (Vanderbilt University). For vaccine safety expertise: Elizabeth Barnett, MD (Boston University), Anna Durbin, MD (Johns Hopkins University), Neal Halsey, MD (Johns Hopkins University), Nicola Klein, MD, PhD (Kaiser Permanente Northern California), Philip LaRussa M.D. (Columbia University), Stephen Pelton, MD (Boston University), Elizabeth Schlaudecker, MD, MPH (Cincinnati Children\u2019s Hospital Medical Center), Michael Smith, MD, MSCE (Duke University), Mary Staat, MD, MPH (Cincinnati Children\u2019s Hospital Medical Center), and Melissa Stockwell (Columbia University). We would also like to thank the clinical staff who have cared for these patients and who reported these events to VAERS.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.1\u0022 data-doi=\u002210.1056\/NEJMoa2104840\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGreinacher\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThiele\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWarkentin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeisser\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKyrle\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEichinger\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 3;\u003Cspan class=\u0022cit-vol\u0022\u003E384\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E22\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2092\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2101\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D384%26rft.spage%253D2092%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2104840%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2104840\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchultz\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ENH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ES\u00f8rvoll\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMichelsen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 3;\u003Cspan class=\u0022cit-vol\u0022\u003E384\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E22\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2124\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2130\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DThrombosis%2Band%2BThrombocytopenia%2Bafter%2BChAdOx1%2BnCoV-19%2BVaccination%26rft.volume%253D384%26rft.spage%253D2124%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.3\u0022 data-doi=\u002210.1056\/NEJMoa2105385\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EScully\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESingh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELown\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPathologic antibodies to platelet factor 4 after ChAdOx1 nCov-19 vaccination\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 10;\u003Cspan class=\u0022cit-vol\u0022\u003E384\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E23\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2202\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2211\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D384%26rft.spage%253D2202%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2105385%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2105385\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2021.11.10.21266063v1.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShay\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGee\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety monitoring of the Janssen (Johnson \u0026amp; Johnson) COVID-19 vaccine \u2014 United States, March\u2013April 2021\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMMWR Morb Mortal Wkly Rep\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EMay\u003C\/span\u003E 7;\u003Cspan class=\u0022cit-vol\u0022\u003E70\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E18\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E680\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E684\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMMWR%2BMorb%2BMortal%2BWkly%2BRep%26rft.volume%253D70%26rft.spage%253D680%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESee\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELale\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EU.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination\u2014March 2 to April 21, 2021\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 22;\u003Cspan class=\u0022cit-vol\u0022\u003E325\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E24\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2448\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2456\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft.volume%253D325%26rft.spage%253D2448%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EReuters news\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ENorway drops AstraZeneca vaccine, J\u0026amp;J remains on hold\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 3, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/norway-will-not-use-astrazeneca-covid-19-vaccine-says-daily-vg-2021-05-12\/\u0022\u003Ehttps:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/norway-will-not-use-astrazeneca-covid-19-vaccine-says-daily-vg-2021-05-12\/\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMacNeil\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBroder\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUpdated Recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson \u0026amp; Johnson) COVID-19 Vaccine after Reports of Thrombosis with Thrombocytopenia Syndrome among vaccine recipients\u2013 United States, April 2021\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMMWR Morb Mortal Wkly Rep\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EApr\u003C\/span\u003E 30;\u003Cspan class=\u0022cit-vol\u0022\u003E70\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E17\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E651\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E656\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMMWR%2BMorb%2BMortal%2BWkly%2BRep%26rft.volume%253D70%26rft.spage%253D651%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EGlobal Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield)\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.who.int\/news\/item\/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)\u0022\u003Ehttps:\/\/www.who.int\/news\/item\/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield\u003C\/a\u003E). Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 3, 2021\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EPublic Health Agency of Canada\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Recommendations on the use of COVID-19 vaccines\u003C\/span\u003E. Published July 22, 2021. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 2, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines\/recommendations-use-covid-19-vaccines-en.pdf%C3%A3hq_e=el\u0026amp;hq_m=2184507\u0026amp;hq_l=1\u0026amp;hq_v=911ba6e5ee\u0022\u003Ehttps:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines\/recommendations-use-covid-19-vaccines-en.pdf\u00e3hq_e=el\u0026amp;hq_m=2184507\u0026amp;hq_l=1\u0026amp;hq_v=911ba6e5ee\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2021.11.10.21266063v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAustralian Government Department of Health Therapeutic Goods Administration\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ECOVID-19 vaccine weekly safety report \u2013 02-09-2021\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 2, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-02-09-2021\u0022\u003Ehttps:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-02-09-2021\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EUnited Kingdom Medicines \u0026amp; Healthcare products Regulatory Agency\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EResearch and analysis: Coronavirus vaccine \u2013 weekly summary of Yellow Card reporting updated 2 September 2021\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 2, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports\u0022\u003Ehttps:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.12\u0022 data-doi=\u002210.1182\/blood-2014-01-549741\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWarkentin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBasciano\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKnopman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBernstein\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERA\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESpontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBlood\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 5;\u003Cspan class=\u0022cit-vol\u0022\u003E123\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E23\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E3651\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E4\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBlood%26rft_id%253Dinfo%253Adoi%252F10.1182%252Fblood-2014-01-549741%26rft_id%253Dinfo%253Apmid%252F24677540%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6ImJsb29kam91cm5hbCI7czo1OiJyZXNpZCI7czoxMToiMTIzLzIzLzM2NTEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMS8xNC8yMDIxLjExLjEwLjIxMjY2MDYzLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESahu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJindal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAnderson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiddiqui\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAD\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJaiyesimi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIA\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECurrent Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Blood Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EAug\u003C\/span\u003E 17;\u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E267\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E277\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BBlood%2BMed%26rft.volume%253D11%26rft.spage%253D267%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.14\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGreinacher\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESelleng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWesche\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ETowards Understanding ChAdOx1 nCoV-19 Vaccine-induced Thrombotic Thrombocytopenia (VITT)\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPreprint on ResearchSquare\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.researchsquare.com\/article\/rs-440461\/v1\u0022\u003Ehttps:\/\/www.researchsquare.com\/article\/rs-440461\/v1\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKowarz\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKrutzke\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EReis\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003E\u201cVaccine-Induced Covid-19 Mimicry\u201d Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EPreprint on ResearchSquare\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.researchsquare.com\/article\/rs-558954\/v1\u0022\u003Ehttps:\/\/www.researchsquare.com\/article\/rs-558954\/v1\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPavord\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EScully\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHunt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical features of vaccine-induced immune thrombocytopenia and thrombosis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EAug\u003C\/span\u003E 11. Online ahead of print.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESangli\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVirani\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECheronis\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThrombosis with Thrombocytopenia after the messenger RNA-1273 Vaccine\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Intern Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E 29:L21-0244. Online ahead of print.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.18\u0022 data-doi=\u002210.1016\/j.vaccine.2015.07.035\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShimabukuro\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENguyen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESafety monitoring in the Vaccine Adverse Event Reporting System (VAERS)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVaccine\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EAug\u003C\/span\u003E 26;\u003Cspan class=\u0022cit-vol\u0022\u003E33\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E36\u003C\/span\u003E);\u003Cspan class=\u0022cit-fpage\u0022\u003E4398\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E405\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DVaccine%26rft.volume%253D33%26rft.spage%253D4398%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.vaccine.2015.07.035%26rft_id%253Dinfo%253Apmid%252F26209838%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.vaccine.2015.07.035\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26209838\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWelcome to MedDRA: Medical Dictionary for Regulatory Activities\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 3, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.meddra.org\/\u0022\u003Ehttps:\/\/www.meddra.org\/\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003ECOVID-19 Vaccinations in the United States\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 7, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total\u0022\u003Ehttps:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECenters for Disease Control and Prevention\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EClinical Immunization Safety Assessment (CISA) Project\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 7, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/cisa\/index.html\u0022\u003Ehttps:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/cisa\/index.html\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.22\u0022 data-doi=\u002210.1016\/j.jbi.2008.08.010\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarris\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaylor\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThielke\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EResearch electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Biomed Inform\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EApr\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E42\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E377\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E81\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bbiomedical%2Binformatics%26rft.stitle%253DJ%2BBiomed%2BInform%26rft.aulast%253DHarris%26rft.auinit1%253DP.%2BA.%26rft.volume%253D42%26rft.issue%253D2%26rft.spage%253D377%26rft.epage%253D381%26rft.atitle%253DResearch%2Belectronic%2Bdata%2Bcapture%2B%2528REDCap%2529--a%2Bmetadata-driven%2Bmethodology%2Band%2Bworkflow%2Bprocess%2Bfor%2Bproviding%2Btranslational%2Bresearch%2Binformatics%2Bsupport.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jbi.2008.08.010%26rft_id%253Dinfo%253Apmid%252F18929686%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jbi.2008.08.010\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=18929686\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000264958800018\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.23\u0022 data-doi=\u002210.1016\/j.jbi.2019.103208\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarris\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETaylor\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMinor\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe REDCap consortium: Building an international community of software partners\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Biomed Inform\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJul\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E95\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E103208\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BBiomed%2BInform%26rft.volume%253D95%26rft.spage%253D103208%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jbi.2019.103208%26rft_id%253Dinfo%253Apmid%252F31078660%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jbi.2019.103208\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31078660\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.24\u0022 data-doi=\u002210.1111\/j.1365-2141.2010.08206.x\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELijfering\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EWM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERosendaal\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EFR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECannegieter\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESC\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERisk factors for venous thrombosis \u2013 current understanding from an epidemiological point of view\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBr J Haematol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJun\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E149\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E6\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E824\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E33\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBritish%2Bjournal%2Bof%2Bhaematology%26rft.stitle%253DBr%2BJ%2BHaematol%26rft.aulast%253DLijfering%26rft.auinit1%253DW.%2BM.%26rft.volume%253D149%26rft.issue%253D6%26rft.spage%253D824%26rft.epage%253D833%26rft.atitle%253DRisk%2Bfactors%2Bfor%2Bvenous%2Bthrombosis%2B-%2Bcurrent%2Bunderstanding%2Bfrom%2Ban%2Bepidemiological%2Bpoint%2Bof%2Bview.%26rft_id%253Dinfo%253Adoi%252F10.1111%252Fj.1365-2141.2010.08206.x%26rft_id%253Dinfo%253Apmid%252F20456358%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1111\/j.1365-2141.2010.08206.x\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20456358\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000277973400003\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-25-1\u0022 title=\u0022View reference 25. in text\u0022 id=\u0022ref-25\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrous-Bou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarrington\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELB\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKabrhel\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEnvironmental and genetic risk factors associated with venous thromboembolism\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESemin Thromb Hemost\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003ENov\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E42\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E8\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E808\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E820\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSemin%2BThromb%2BHemost%26rft.volume%253D42%26rft.spage%253D808%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26. in text\u0022 id=\u0022ref-26\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.26\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAmerican Society of Hematology\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EThrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia)\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 8, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia\u0022\u003Ehttps:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E27.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-27-1\u0022 title=\u0022View reference 27. in text\u0022 id=\u0022ref-27\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.27\u0022 data-doi=\u002210.1212\/WNL.0000000000012576\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWalter\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EU\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFuchs\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGrossmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAdenovirus-vectored COVID-19 vaccine-induced immune thrombosis of carotid artery: a case report\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENeurology\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJul\u003C\/span\u003E 26;\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-doi\u0022\u003Edoi:\u003C\/span\u003E10.1212\/WNL.0000000000012576\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E.\u003C\/span\u003E Online ahead of print\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNeurology%26rft_id%253Dinfo%253Adoi%252F10.1212%252FWNL.0000000000012576%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1212\/WNL.0000000000012576\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E28.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 28. in text\u0022 id=\u0022ref-28\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.28\u0022 data-doi=\u002210.1182\/blood.2021011958\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETiede\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESachs\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EUJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECzwalinna\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProthrombotic immune thrombocytopenia after COVID-19 vaccination\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBlood\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJul\u003C\/span\u003E 29; \u003Cspan class=\u0022cit-vol\u0022\u003E138\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E350\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E353\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBlood%26rft.volume%253D138%26rft.spage%253D350%26rft_id%253Dinfo%253Adoi%252F10.1182%252Fblood.2021011958%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1182\/blood.2021011958\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2021%2F11%2F14%2F2021.11.10.21266063.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E29.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-29-1\u0022 title=\u0022View reference 29. in text\u0022 id=\u0022ref-29\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.29\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESalih\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESch\u00f6nborn\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKohler\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EVaccine-Induced Thrombocytopenia with Severe Headache\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003ESep\u003C\/span\u003E 15. Online ahead of print.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E30.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-30-1\u0022 title=\u0022View reference 30. in text\u0022 id=\u0022ref-30\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2021.11.10.21266063v1.30\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EAssociated Press\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EUS recommends \u2018pause\u2019 for J\u0026amp;J shots in blow to vaccine drive\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ESeptember 14, 2021\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/apnews.com\/article\/us-pause-j-and-j-vaccine-blood-clot-reports-2dde2aacf486bab59844ef907a28cbce\u0022\u003Ehttps:\/\/apnews.com\/article\/us-pause-j-and-j-vaccine-blood-clot-reports-2dde2aacf486bab59844ef907a28cbce\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E31.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 31. in text\u0022 id=\u0022ref-31\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.31\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuynh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKelton\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArnold\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDaka\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENazy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAntibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EAug\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E596\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E7873\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E565\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E569\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%26rft.volume%253D596%26rft.spage%253D565%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E32.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-32-1\u0022 title=\u0022View reference 32. in text\u0022 id=\u0022ref-32\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.32\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVayne\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERollin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGruel\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPF4 immunoassays in vaccine-induced thrombotic thrombocytopenia\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EJuly\u003C\/span\u003E 22;\u003Cspan class=\u0022cit-vol\u0022\u003E385\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E3765\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E378\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D385%26rft.spage%253D3765%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E33.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-33-1\u0022 title=\u0022View reference 33. in text\u0022 id=\u0022ref-33\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.33\u0022 data-doi=\u002210.15585\/mmwr.mm7032e4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERosenblum\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHG\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHadler\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMoulia\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson \u0026amp; Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices \u2014 United States, July 2021\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMMWR Morb Mortal Wkly Rep\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EAug\u003C\/span\u003E 13;\u003Cspan class=\u0022cit-vol\u0022\u003E70\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E32\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1094\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1099\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMMWR%2BMorb%2BMortal%2BWkly%2BRep%26rft.volume%253D70%26rft.spage%253D1094%26rft_id%253Dinfo%253Adoi%252F10.15585%252Fmmwr.mm7032e4%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.15585\/mmwr.mm7032e4\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E34.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-34-1\u0022 title=\u0022View reference 34. in text\u0022 id=\u0022ref-34\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2021.11.10.21266063v1.34\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECusters\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKim\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeyssen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EVaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVaccine\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EMay\u003C\/span\u003E 21;\u003Cspan class=\u0022cit-vol\u0022\u003E39\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E22\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E3081\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E3101\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DVaccine%26rft.volume%253D39%26rft.spage%253D3081%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E35.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2021.11.10.21266063v1.35\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeitz\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJI\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFredenburgh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEikelbloom\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJW\u003C\/span\u003E\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EA test in context: D-dimer\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003ENov\u003C\/span\u003E 7;\u003Cspan class=\u0022cit-vol\u0022\u003E70\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E19\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2411\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2420\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DA%2Btest%2Bin%2Bcontext%253A%2BD-dimer%26rft.volume%253D70%26rft.spage%253D2411%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}